Shopping Cart 0
Cart Subtotal
AED 0

Camurus AB (CAMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Camurus AB (Camurus), a subsidiary of Sandberg Development AB, is a pharmaceutical company that carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company's technology includes smart and versatile drug delivery, injection depot, nanoparticles and topical, bioadhesive. It offers its products through its proprietary FluidCrystal brand. Camurus' FluidCrystal technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. The company products have therapeutic applications in the areas of cancer, endocrine disorders, pain, oral mucositis, metabolic disease, growth hormone disorders and drug addiction. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development. Camurus is headquartered in Lund, Sweden.

Camurus AB (CAMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Camurus AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Camurus AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Camurus AB, Medical Devices Deals, 2012 to YTD 2018 10

Camurus AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Camurus AB, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Camurus and Medison Pharma Enter into Agreement 12

Camurus Enters into Distribution Agreement with Ethypharm 13

Licensing Agreements 14

Solasia Pharma Enters into Licensing Agreement with Camurus 14

Braeburn Pharma Enters into Licensing Agreement with Camurus 15

R-Pharm Enters into Licensing Agreement with Camurus 16

Rhythm Pharma Enters into Licensing Agreement with Camurus 17

Solasia Pharma Enters into Licensing Agreement with Camurus for episil Oral Liquid 18

Camurus Expands Licensing Agreement with Braeburn Pharma 19

Camurus Enters Into Licensing Agreement With Cangene For Episil 21

Equity Offering 22

Camurus Raises USD11.5 Million in Private Placement of Shares 22

Camurus Completes IPO 24

Acquisition 26

Swedbank Robur Fonder Acquires 8.31% Stake in Camurus 26

Camurus AB-Key Competitors 27

Camurus AB-Key Employees 28

Camurus AB-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Jul 17, 2018: Camurus: Interim Report January-June 2018 30

May 03, 2018: Camurus: Interim Report January-March 2018 32

Feb 15, 2018: Camurus: Full year report 2017 34

Oct 26, 2017: Camurus: Interim Report January-September 2017 36

Jul 13, 2017: Camurus: Interim report January-June 2017 38

May 03, 2017: Camurus Announces Interim Report January-March 2017 40

Feb 16, 2017: Camurus Announces Full year report 2016 42

Product News 44

11/07/2017: Camurus to present at Jefferies 2017 London Healthcare Conference 44

11/01/2017: Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder 45

10/10/2018: Camurus to present at Jefferies 2018 London Healthcare Conference 46

10/05/2017: Braeburn CEO Participates in U.S. Department of Health and Human Services Secretarial Roundtable Discussion on Opioids 47

09/27/2017: Braeburn Participates in President's Commission Meeting on Combating Drug Addiction and the Opioid Crisis 48

09/21/2018: CAM2038 receives positive CHMP opinion for the treatment of opioid dependence in Europe 49

09/18/2017: Camurus Announces that FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder 50

05/25/2018: Camurus to present at the Jefferies 2018 Global Healthcare Conference 51

Product Approvals 52

Jul 16, 2018: Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder 52

May 28, 2018: Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder 53

Jan 21, 2018: Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot 54

Oct 30, 2017: Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting 55

Sep 29, 2017: Camurus Announces European Medicines Agency Validation of CAM2038 Marketing Authorization Application for Treatment of Opioid Dependence 56

Jul 20, 2017: Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder 57

Clinical Trials 59

Sep 18, 2018: Camurus announces positive topline phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain 59

May 14, 2018: Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine 60

May 14, 2018: JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus' long-acting buprenorphine depots for opioid use disorder 61

Jul 12, 2017: Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain 63

Jun 22, 2017: Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms 65

Jun 15, 2017: Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine 66

May 02, 2017: Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038 67

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

Camurus AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Camurus AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Camurus AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Camurus AB, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Camurus AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Camurus AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Camurus AB, Deals By Therapy Area, 2012 to YTD 2018 9

Camurus AB, Medical Devices Deals, 2012 to YTD 2018 10

Camurus AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Camurus and Medison Pharma Enter into Agreement 12

Camurus Enters into Distribution Agreement with Ethypharm 13

Solasia Pharma Enters into Licensing Agreement with Camurus 14

Braeburn Pharma Enters into Licensing Agreement with Camurus 15

R-Pharm Enters into Licensing Agreement with Camurus 16

Rhythm Pharma Enters into Licensing Agreement with Camurus 17

Solasia Pharma Enters into Licensing Agreement with Camurus for episil Oral Liquid 18

Camurus Expands Licensing Agreement with Braeburn Pharma 19

Camurus Enters Into Licensing Agreement With Cangene For Episil 21

Camurus Raises USD11.5 Million in Private Placement of Shares 22

Camurus Completes IPO 24

Swedbank Robur Fonder Acquires 8.31% Stake in Camurus 26

Camurus AB, Key Competitors 27

Camurus AB, Key Employees 28

Camurus AB, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Camurus AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Camurus AB (Camurus), a subsidiary of Sandberg Development AB, is a pharmaceutical company that carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company's technology includes smart and versatile drug delivery, injection depot, nanoparticles and topical, bioadhesive. It offers its products through its proprietary FluidCrystal brand. Camurus' FluidCrystal technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. The company products have therapeutic applications in the areas of cancer, endocrine disorders, pain, oral mucositis, metabolic disease, growth hormone disorders and drug addiction. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development. Camurus is headquartered in Lund, Sweden.

Camurus AB (CAMX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Camurus AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Camurus AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Camurus AB, Medical Devices Deals, 2012 to YTD 2018 10

Camurus AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Camurus AB, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Camurus and Medison Pharma Enter into Agreement 12

Camurus Enters into Distribution Agreement with Ethypharm 13

Licensing Agreements 14

Solasia Pharma Enters into Licensing Agreement with Camurus 14

Braeburn Pharma Enters into Licensing Agreement with Camurus 15

R-Pharm Enters into Licensing Agreement with Camurus 16

Rhythm Pharma Enters into Licensing Agreement with Camurus 17

Solasia Pharma Enters into Licensing Agreement with Camurus for episil Oral Liquid 18

Camurus Expands Licensing Agreement with Braeburn Pharma 19

Camurus Enters Into Licensing Agreement With Cangene For Episil 21

Equity Offering 22

Camurus Raises USD11.5 Million in Private Placement of Shares 22

Camurus Completes IPO 24

Acquisition 26

Swedbank Robur Fonder Acquires 8.31% Stake in Camurus 26

Camurus AB-Key Competitors 27

Camurus AB-Key Employees 28

Camurus AB-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Jul 17, 2018: Camurus: Interim Report January-June 2018 30

May 03, 2018: Camurus: Interim Report January-March 2018 32

Feb 15, 2018: Camurus: Full year report 2017 34

Oct 26, 2017: Camurus: Interim Report January-September 2017 36

Jul 13, 2017: Camurus: Interim report January-June 2017 38

May 03, 2017: Camurus Announces Interim Report January-March 2017 40

Feb 16, 2017: Camurus Announces Full year report 2016 42

Product News 44

11/07/2017: Camurus to present at Jefferies 2017 London Healthcare Conference 44

11/01/2017: Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder 45

10/10/2018: Camurus to present at Jefferies 2018 London Healthcare Conference 46

10/05/2017: Braeburn CEO Participates in U.S. Department of Health and Human Services Secretarial Roundtable Discussion on Opioids 47

09/27/2017: Braeburn Participates in President's Commission Meeting on Combating Drug Addiction and the Opioid Crisis 48

09/21/2018: CAM2038 receives positive CHMP opinion for the treatment of opioid dependence in Europe 49

09/18/2017: Camurus Announces that FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder 50

05/25/2018: Camurus to present at the Jefferies 2018 Global Healthcare Conference 51

Product Approvals 52

Jul 16, 2018: Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder 52

May 28, 2018: Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder 53

Jan 21, 2018: Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot 54

Oct 30, 2017: Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting 55

Sep 29, 2017: Camurus Announces European Medicines Agency Validation of CAM2038 Marketing Authorization Application for Treatment of Opioid Dependence 56

Jul 20, 2017: Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder 57

Clinical Trials 59

Sep 18, 2018: Camurus announces positive topline phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain 59

May 14, 2018: Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine 60

May 14, 2018: JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus' long-acting buprenorphine depots for opioid use disorder 61

Jul 12, 2017: Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain 63

Jun 22, 2017: Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms 65

Jun 15, 2017: Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine 66

May 02, 2017: Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038 67

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69


List Of Figure

List of Figures

Camurus AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Camurus AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Camurus AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Camurus AB, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Camurus AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Camurus AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Camurus AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Camurus AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Camurus AB, Deals By Therapy Area, 2012 to YTD 2018 9

Camurus AB, Medical Devices Deals, 2012 to YTD 2018 10

Camurus AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Camurus and Medison Pharma Enter into Agreement 12

Camurus Enters into Distribution Agreement with Ethypharm 13

Solasia Pharma Enters into Licensing Agreement with Camurus 14

Braeburn Pharma Enters into Licensing Agreement with Camurus 15

R-Pharm Enters into Licensing Agreement with Camurus 16

Rhythm Pharma Enters into Licensing Agreement with Camurus 17

Solasia Pharma Enters into Licensing Agreement with Camurus for episil Oral Liquid 18

Camurus Expands Licensing Agreement with Braeburn Pharma 19

Camurus Enters Into Licensing Agreement With Cangene For Episil 21

Camurus Raises USD11.5 Million in Private Placement of Shares 22

Camurus Completes IPO 24

Swedbank Robur Fonder Acquires 8.31% Stake in Camurus 26

Camurus AB, Key Competitors 27

Camurus AB, Key Employees 28

Camurus AB, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Camurus AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.